Legal & General Group Plc raised its position in Johnson & Johnson (NYSE:JNJ) by 1.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,671,764 shares of the company’s stock after acquiring an additional 308,234 shares during the period. Johnson & Johnson comprises approximately 1.4% of Legal & General Group Plc’s holdings, making the stock its 6th largest holding. Legal & General Group Plc owned 0.67% of Johnson & Johnson worth $2,317,329,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the business. University of Texas Texas AM Investment Managment Co. bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $31,000. Sofos Investments Inc. lifted its position in Johnson & Johnson by 172.0% in the first quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock worth $33,000 after purchasing an additional 726 shares during the period. Altshuler Shaham Ltd acquired a new stake in Johnson & Johnson during the first quarter worth $35,000. Advocacy Wealth Management Services LLC increased its holdings in Johnson & Johnson by 38.2% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 300 shares of the company’s stock valued at $39,000 after buying an additional 83 shares during the period. Finally, Lion Street Advisors LLC bought a new stake in Johnson & Johnson in the 1st quarter valued at $45,000. Institutional investors own 68.51% of the company’s stock.
Several analysts have recently weighed in on JNJ shares. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Raymond James lifted their price objective on Johnson & Johnson from $153.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Wells Fargo & Co raised Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Credit Suisse Group reaffirmed a “buy” rating and issued a $161.00 price target on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Finally, Bank of America upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $150.00 to $175.00 in a research note on Wednesday, April 22nd. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $163.47.
In other news, Director William D. Perez acquired 500 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were purchased at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the transaction, the director now owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 0.27% of the stock is currently owned by corporate insiders.
Shares of Johnson & Johnson stock traded down $5.78 during trading on Thursday, reaching $142.02. The company’s stock had a trading volume of 615,568 shares, compared to its average volume of 9,788,369. The stock has a 50-day moving average price of $148.74 and a two-hundred day moving average price of $143.64. The stock has a market capitalization of $394.85 billion, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 3.20 and a beta of 0.70. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The firm had revenue of $20.69 billion during the quarter, compared to analysts’ expectations of $19.48 billion. During the same quarter last year, the company posted $2.10 EPS. The company’s quarterly revenue was up 3.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 7.68 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a $1.01 dividend. This represents a $4.04 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend was Friday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s payout ratio is 46.54%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: The limitations of an equal weight rating
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.